CompletedPhase 1

A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies

Netherlands39 participantsStarted 2012-11

Plain-language summary

This study is to determine the appropriate dosing regimen of GS-9820 in subjects with lymphoid malignancies. This is a Phase 1b, open-label, dose-escalation and expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of GS-9820.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Previously treated recurrent B-cell iNHL, DLBCL, MCL, HL or CLL * Measurable lymphadenopathy * Requires therapy Exclusion Criteria: * Recent history of a major non-lymphoid malignancy * Evidence of ongoing infection * Concurrent participation in another therapeutic clinical trial

What they're measuring

Maximum tolerated dose (MTD)

Timeframe: Up to 4 weeks

Trial details

NCT IDNCT01705847

SponsorGilead Sciences

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2016-05

View on ClinicalTrials.gov More Lymphoid Malignancies trials